Role of Tranexamic Acid Reduces Perioperative Blood Loss in Spine Surgery
Not Applicable
Completed
- Conditions
- Surgerypostoperative blood loss
- Registration Number
- PACTR201611001846189
- Lead Sponsor
- Faculty of medicine, Benha university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
ages ranged between 28: 65 years
ASA I and II
BMI < 35 kg/m2
Posterior arthrodesis with fusion of one or two levels
Exclusion Criteria
uncontrolled hypertension
liver or renal impairment
congenital or syndromic scoliosis
fixation of more than 2 levels
Previous spinal surgery
coagulopathies
patients who received anticoagulant or any drug that may interfere with the study drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain tranexamic acid's efficacy in reducing perioperative blood loss during spine surgery?
How does tranexamic acid compare to standard antifibrinolytic agents like aprotinin in spine surgery outcomes?
Are there specific biomarkers that predict response to tranexamic acid in patients undergoing spinal procedures?
What are the potential adverse events associated with high-dose tranexamic acid in orthopedic surgery?
What combination therapies with tranexamic acid show promise for managing postoperative blood loss in spinal surgery?